Shelby D. Gainer

461 total citations
12 papers, 245 citations indexed

About

Shelby D. Gainer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Shelby D. Gainer has authored 12 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Shelby D. Gainer's work include Pancreatic and Hepatic Oncology Research (4 papers), Renal cell carcinoma treatment (4 papers) and Cancer Treatment and Pharmacology (4 papers). Shelby D. Gainer is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Renal cell carcinoma treatment (4 papers) and Cancer Treatment and Pharmacology (4 papers). Shelby D. Gainer collaborates with scholars based in United States, Australia and Spain. Shelby D. Gainer's co-authors include A. Benjamin Suttle, Mohammed M. Dar, Lisa Malburg, Elisabeth I. Heath, Patricia LoRusso, Jeffrey P. Hodge, Thangam Arumugham, Joanne Lager, Howard Ball and Christopher J. Sweeney and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Shelby D. Gainer

12 papers receiving 241 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shelby D. Gainer United States	7	135	123	106	39	34	12	245
Stefanie D. Krens Netherlands	9	117 0.9×	65 0.5×	70 0.7×	31 0.8×	17 0.5×	16	248
Guilherme Harada Brazil	11	155 1.1×	161 1.3×	90 0.8×	19 0.5×	66 1.9×	40	317
Christopher Sweeney United States	9	99 0.7×	162 1.3×	143 1.3×	48 1.2×	70 2.1×	52	361
Qingyu Wang China	10	127 0.9×	76 0.6×	47 0.4×	29 0.7×	25 0.7×	48	264
Anas Al-Janadi United States	8	182 1.3×	91 0.7×	86 0.8×	13 0.3×	45 1.3×	25	309
Mohamad Khasawneh United States	6	93 0.7×	223 1.8×	181 1.7×	21 0.5×	106 3.1×	8	333
Sara Nunnery United States	8	115 0.9×	83 0.7×	158 1.5×	47 1.2×	53 1.6×	15	352
Abhilasha Nair United States	7	107 0.8×	49 0.4×	64 0.6×	17 0.4×	54 1.6×	11	262
Sachi Morita Japan	10	167 1.2×	58 0.5×	102 1.0×	36 0.9×	56 1.6×	25	285
Christopher Sweeney United States	7	174 1.3×	94 0.8×	94 0.9×	15 0.4×	21 0.6×	15	285

Countries citing papers authored by Shelby D. Gainer

Since Specialization

Citations

This map shows the geographic impact of Shelby D. Gainer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shelby D. Gainer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shelby D. Gainer more than expected).

Fields of papers citing papers by Shelby D. Gainer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shelby D. Gainer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shelby D. Gainer. The network helps show where Shelby D. Gainer may publish in the future.

Co-authorship network of co-authors of Shelby D. Gainer

This figure shows the co-authorship network connecting the top 25 collaborators of Shelby D. Gainer. A scholar is included among the top collaborators of Shelby D. Gainer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shelby D. Gainer. Shelby D. Gainer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Voss, Martin H., Benjamin Garmezy, J.P. Maroto Rey, et al.. (2023). 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). Annals of Oncology. 34. S1012–S1012. 7 indexed citations

Albigès, Laurence, Laura Rodríguez, Sang‐We Kim, et al.. (2022). Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.. Journal of Clinical Oncology. 40(16_suppl). 107–107. 15 indexed citations

Tran, Ben, Mark Voskoboynik, Sang‐We Kim, et al.. (2022). Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study. Cancer Research. 82(12_Supplement). CT016–CT016. 3 indexed citations

Koch, Kevin M., E. Claire Dees, Nandi J. Reddy, et al.. (2017). The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 80(6). 1141–1146. 4 indexed citations

Blagden, Sarah P., Hani Gabra, Anne Hamilton, et al.. (2016). Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.. Journal of Clinical Oncology. 34(15_suppl). 2551–2551. 3 indexed citations

Burris, Howard A., Afshin Dowlati, Rebecca A. Moss, et al.. (2012). Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 11(8). 1820–1828. 32 indexed citations

Blackman, Samuel C., Shelby D. Gainer, Benjamin Suttle, et al.. (2012). Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency. Cancer Research. 72(8_Supplement). 1752–1752. 6 indexed citations

Heath, Elisabeth I., Lisa Malburg, Shelby D. Gainer, et al.. (2011). A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Investigational New Drugs. 30(4). 1566–1574. 33 indexed citations

Johnson, Brendan M., Laurel M. Adams, Ke Zhang, et al.. (2010). Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin‐1 Receptor Antagonist. The Journal of Clinical Pharmacology. 50(8). 951–959. 13 indexed citations

10.

Heath, Elisabeth I., E. Gabriela Chiorean, Christopher J. Sweeney, et al.. (2010). A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics. 88(6). 818–823. 85 indexed citations

11.

Tan, Antoinette R., Afshin Dowlati, Suzanne F. Jones, et al.. (2010). Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors. The Oncologist. 15(12). 1253–1261. 40 indexed citations

12.

Burris, Howard A., Andreas du Bois, Afshin Dowlati, et al.. (2009). Abstract A6: Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: Results of two phase I studies. Molecular Cancer Therapeutics. 8(12_Supplement). A6–A6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact